XTL Biopharmaceuticals Ltd. XTLB
2.20
(0.21)
(8.71%)
as of 25 Sep
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
P/S ratio |
— | — | — | — | — | — | — | — | 5.63 | — |
P/FCF ratio |
— | — | — | — | — | — | — | — | 0.00 | — |
P/Operating CF |
— | — | — | — | — | — | — | — | (17.84) | — |
P/B ratio |
— | — | — | — | — | — | — | — | 1.93 | — |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/Sales |
— | — | — | — | — | — | — | — | 4.84 | — |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | — | — | — | (2.70) | — |
EV/FCF |
— | — | — | — | — | — | — | — | (2.56) | — |
Quick Ratio |
8.35 | 12.33 | 32.39 | 29.44 | 23.79 | 26.52 | 19.90 | 9.93 | 0.56 | 0.18 |
Current Ratio |
8.35 | 20.69 | 32.39 | 29.44 | 24.10 | 27.00 | 20.35 | 9.93 | 0.61 | 0.40 |
Net Debt/EBITDA |
1.42 | 2.88 | 10.24 | 7.99 | 6.38 | 5.95 | 4.23 | 2.62 | 1.74 | (0.11) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.61% | 162.05% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | (1.06) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.68 | 1.44 | (0.27) | 0.67 | 0.29 | (2.41) | 0.67 | 0.40 | 1.58 | 0.15 |
Capex/Depreciation |
(0.08) | 0.96 | — | 0.00 | (1.00) | 0.00 | 0.00 | — | (0.27) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (67.20%) | (24.77%) | 50.01% | (17.61%) | (55.78%) | 9.73% | (28.89%) | (57.31%) | (26.83%) | (269.02%) | |
| (61.03%) | (16.27%) | 39.39% | (17.06%) | (43.08%) | 6.63% | (24.95%) | (53.90%) | (18.71%) | (159.91%) | |
ROIC |
(630.17%) | (2,433.59%) | (247.81%) | (208.83%) | 0.00% | 0.00% | (197.84%) | (223.42%) | (10.93%) | 0.00% |
Return on Tangible Assets |
(104.56%) | (13.22%) | 37.60% | (20.41%) | (50.33%) | 7.24% | (37.25%) | (96.85%) | 151.03% | 2,743.70% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.08 | 0.06 | 0.04 | 0.05 | 0.06 | 0.06 | 0.09 | 0.16 | 0.82 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | — | — | (0.14) | — |
Graham Number |
— | — | — | — | — | — | — | — | 0.00 | — |
Earnings Yield |
— | — | — | — | — | — | — | — | (3.45%) | — |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | (33.61%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.53) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.24) | (0.11) |
Capex per Share |
(0.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
(2.62) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.25) | (0.11) |
Cash per Share |
3.55 | 3.05 | 6.32 | 5.23 | 4.70 | 4.61 | 2.73 | 1.47 | 0.17 | 0.01 |
Shareholders Equity per Share |
3.92 | 3.08 | 6.47 | 5.43 | 2.81 | 4.01 | 2.94 | 1.63 | 0.81 | (0.03) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.92 | 3.08 | 6.47 | 5.43 | 2.81 | 4.01 | 2.94 | 1.63 | 0.81 | (0.03) |
Free Cash Flow |
(1.80) | (1.12) | (0.82) | (0.91) | (0.85) | (1.05) | (0.90) | (0.71) | (1.67) | (1.02) |
Working Capital |
2.42 | 5.91 | 7.94 | 6.60 | 5.87 | 6.01 | 3.62 | 1.84 | (0.87) | (0.25) |
Capital Expenditures |
(0.07) | 0.00 | — | 0.00 | 0.00 | — | — | — | (0.05) | — |
Net Current Asset Value |
2.42 | 3.24 | 7.94 | 6.60 | 3.23 | 4.95 | 3.62 | 1.84 | (1.77) | (0.25) |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | — | — | — | — | — | — | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
85.10 | 0.00 | — | 0.00 | 0.50 | 1.00 | 0.00 | — | 1.06 | — |
Cash ROIC |
(34.02%) | (15.61%) | (4.96%) | (6.64%) | (8.83%) | (9.16%) | (11.67%) | (16.73%) | (26.88%) | (1,126.37%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Average Receivables |
0.26 | 0.22 | 0.09 | 0.09 | — | — | — | 0.07 | 0.07 | — |
Average Payables |
0.07 | 0.16 | 0.28 | 0.24 | 0.24 | 0.24 | 0.21 | 0.20 | 0.50 | 0.47 |
Average Assets |
4.17 | 4.80 | 7.58 | 7.89 | 6.86 | 6.56 | 5.40 | 3.31 | 5.49 | 4.36 |
Average Common Equity |
3.79 | 3.15 | 5.97 | 7.65 | 5.30 | 4.47 | 4.67 | 3.11 | 3.83 | 2.59 |
Columns are period end dates